FT US Pharma and Biotech Summit 2020

FT US Pharma and Biotech Summit 2020 is organized by Financial Times (FT) Live and will be held on Sep 29, 2020 at Convene, New York City, New York, USA.

Who Attends:
The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:
• Pharmaceutical & Biotechnology Companies
• Pharmaceutical Wholesalers/PBMs
• CROs
• Healthcare insurers and government payers
• Regulators
• Government healthcare departments and agencies
• IT, big data and analytics providers
• Medical Device Manufacturers
• Investment bankers, private equity and VCs
• Patient representatives and health-related NGOs

Overview:
The 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries today. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the future of gene editing, tracking China’s pharma growth market and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.

Why Attend:
• Gain insights into the healthcare reforms being proposed by US Presidential candidates and how they might affect pharma pricing and risk
• Hear how payer’ perspectives on value is evolving
• Discuss the challenges and opportunities of unconventional partnerships in pharma and the myth and reality of pharma’s digital divide
• Debate whether governments should play a bigger role in drug development as ROI diminishes, shortages increase and price of drugs continue to rise
• Get the inside story on whether China will be a leader or follower in life sciences as the county’s level of ambition and innovation increases
• Discover the latest development in gene editing and have your say on where we should draw the line between risk and opportunity